Strategic Acquisition LakePharma is now part of Curia, highlighting potential cross-sell opportunities within an expanded global CRDMO platform. Leverage Curia’s broader capabilities to position integrated biologics development and manufacturing solutions to existing LakePharma clients and prospects seeking end-to-end support.

Biologics Focus Strong emphasis on antibody discovery, protein engineering, cell line development, and GMP manufacturing presents a compelling case for selling upstream and downstream bioprocess services, especially to biotech firms advancing biologics programs into clinical and commercial stages.

Geographic Footprint Five facilities across key East and West Coast biopharma hubs create opportunities for regional project ظرفیت, faster timelines, and localized support. Target companies prioritizing US-based CRDMO partnerships with reliable domestic supply chains.

Past Vaccine Initiatives Historical involvement in COVID-19 vaccine collaboration and ADC development partnerships indicates capability in rapid response and scalable manufacturing. Use these references to engage vaccine, therapeutics, or platform-based programs needing agile production capability.

Financials Tailwinds Revenue in the tens of millions range with a $30M funding base suggests that there is growth capital and scale-up potential. Propose tiered engagement models from discovery through GMP manufacturing to align with clients at various development stages and funding trajectories.